New
HealthMore in Health→
New GLP-3 Agonist Retatrutide Slashes Weight and Blood Sugar in Phase III Trial
A Phase III trial of retatrutide, a triple-receptor agonist, shows dramatic reductions in HbA1c and body weight in adults with type 2 diabetes, outperforming placebo.
Key Takeaways
- Retatrutide is a GLP-3 agonist targeting GIP, GLP-1, and glucagon receptors.
- Phase III trial enrolled 537 adults with type 2 diabetes across 48 sites.
DE
DT Editorial Team··via medicalxpress.com